Retifanlimab

Unassigned

New Medicines

Anal cancer - advanced squamous cell carcinoma (SCC) that has progressed following no more than two prior systematic treatments of which a least one was platinum-based chemotherapy

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Programmed cell death 1 (PD-1) inhibitor. It is a humanised, hinge-stabilised immunoglobulin G4 (IgG4) monoclonal antibody that blocks the interaction of PD-1 with programmed cell death ligands 1 and 2 (PD-L1 and PD-L2).
Anal cancers are relatively rare tumours. However, their incidence is increasing, particularly among men who have sex with other men, due to widespread infection by human papillomavirus. The annual incidence in the UK is about 1.5 in 100,000 [1].
Anal cancer - advanced squamous cell carcinoma (SCC) that has progressed following no more than two prior systematic treatments of which a least one was platinum-based chemotherapy
Intravenous infusion

Further information

Yes
To be confirmed

Evidence based evaluations

Recurrent advanced locoregional or metastatic Merkel cell carcinoma (MCC) not amenable to surgery or radiation

Information

New molecular entity
Incyte
Incyte

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Programmed cell death 1 (PD-1) inhibitor. It is a humanised, hinge-stabilised immunoglobulin G4 (IgG4) monoclonal antibody that blocks the interaction of PD-1 with programmed cell death ligands 1 and 2 (PD-L1 and PD-L2).
MCC is an infrequent but highly aggressive skin cancer. Five-year survival rates are poor, as there are high rates of metastases at primary diagnoses. Recurrences are also common. There is controversy about actual incidence rates which vary considerably between developed countries with majority populations of fair skin types. The total age-adjusted incidence rate in the East of England is 1.78 per 100 000 person-years. Estimated UK cases for 2020 are 920, and 1134 in 2025 [1].
Recurrent advanced locoregional or metastatic Merkel cell carcinoma (MCC) not amenable to surgery or radiation
Intravenous infusion